G9a/GLP PROTAC

Julia Velez1, Yulin Han1, Hyerin Yim1

  • 1Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science, and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

PubMed
概括

首个针对G9a/GLP蛋白质分解的化体 (PROTAC) 降解剂,化合物10 (MS8709),有效降解这些致癌酶. 这种新型治疗方法在治疗依赖G9a/GLP活性的癌症方面表现有前途.